CoChat

Loss of high‐affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: Implications for the failure of cholinergic replacement therapies

Flynn, Donna D., Weinstein, David A., Mash, Deborah C. · 1991 · Annals of Neurology
Cited by 146

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Cholinergic replacement therapies have yielded little or no clinical improvement in Alzheimer's disease (AD). Since the number of postsynaptic muscarinic receptors remains unchanged in the cerebral cortex, the involvement of other neurotransmitter systems may account for this limited efficacy. Alternatively, there may be a defective coupling of the muscarinic receptor with its nucleotide‐binding protein in AD, which would severely limit the ability of cholinergic agonists to activate intracortical second messengers. To address this possibility, we assessed the ability of the putative M1 muscarinic receptor to form high‐affinity agonist‐receptor complexes with guanine nucleotide regulatory proteins in postmortem frontal cortex. Agonist affinity states of the M1 muscarinic receptor were measured by carbachol/[3 H]‐pirenzepine competition. M1 muscarinic receptors exhibited both high (K H) and low (K L) affinities for the agonist carbachol. High‐affinity agonist binding to M1 receptors in postmortem frontal cortex samples from subjects with AD was reduced, demonstrated by an increase in the K H value. Low‐affinity agonist binding (K L value) was unchanged in AD and was not significantly different from the K L value for the uncoupled receptor determined in the presence of guanine nucleotides. The increase in the K H value resulted in a 70% decrease in the average K L/K H ratio for AD as compared to control samples. Choline acetyltransferase activities correlated significantly with the K L/K H ratios (r = 0.73,p < 0.001). These data suggest that the K L/K H ratio for muscarinic agonists may serve as a neurochemical marker of disease severity. The reduced ability of the M1 receptor subtype to form a high‐affinity agonist state in AD may account for the failure of cholinergic replacement therapies to improve specific features of memory and cognition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.410290305

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 146

Metadata

Authors
Flynn, D. D., Weinstein, D. A., & Mash, D. C.
Venue
Annals of Neurology
Publisher
Wiley
Published
1991-03
Volume
29
Issue
3
Pages
256-262
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W2102305385
Cited by
146
References
4
FWCI
4.31
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Loss of high‐affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: Implications for the failure of cholinergic replacement therapies. https://app.cochat.ai/papers/10.1002/ana.410290305
The paper
Flynn, D. D., Weinstein, D. A., & Mash, D. C. (1991). Loss of high‐affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: Implications for the failure of cholinergic replacement therapies. Annals of Neurology. https://doi.org/10.1002/ana.410290305

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.